Abstract
Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic carbonyls, modulation of retinoic acid level, and regulation of cellular fatty acid synthesis and lipid metabolism. Studies have suggested that AKR1B10 may be a useful biomarker for cancer diagnosis and a potential target for cancer treatment. Over the last decade, a number of AKR1B10 inhibitors including aldose reductase inhibitors (ARIs), endogenous substances, natural-based derivatives and synthetic compounds have been developed, which could be novel anticancer drugs. This review provides an overview on related articles and patents about AKR1B10 inhibitors, with a focus on their inhibition selectivity and mechanism of function.
Keywords: AKR1B10, Aldo-keto reductase, ARL-1, cancer, chemoresistance, inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Volume: 11 Issue: 2
Author(s): Li Huang, Rongzhang He, Weihao Luo, Yuan-Shan Zhu, Jia Li, Tan Tan, Xi Zhang, Zheng Hu and Dixian Luo
Affiliation:
Keywords: AKR1B10, Aldo-keto reductase, ARL-1, cancer, chemoresistance, inhibitors.
Abstract: Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic carbonyls, modulation of retinoic acid level, and regulation of cellular fatty acid synthesis and lipid metabolism. Studies have suggested that AKR1B10 may be a useful biomarker for cancer diagnosis and a potential target for cancer treatment. Over the last decade, a number of AKR1B10 inhibitors including aldose reductase inhibitors (ARIs), endogenous substances, natural-based derivatives and synthetic compounds have been developed, which could be novel anticancer drugs. This review provides an overview on related articles and patents about AKR1B10 inhibitors, with a focus on their inhibition selectivity and mechanism of function.
Export Options
About this article
Cite this article as:
Huang Li, He Rongzhang, Luo Weihao, Zhu Yuan-Shan, Li Jia, Tan Tan, Zhang Xi, Hu Zheng and Luo Dixian, Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (2) . https://dx.doi.org/10.2174/1574892811888160304113346
DOI https://dx.doi.org/10.2174/1574892811888160304113346 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Studying Interactions of Drugs with Cell Membrane Nutrient Transporters: New Frontiers of Proteoliposome Nanotechnology
Current Pharmaceutical Design Benzo[a]pyrene Toxicity and Inflammatory Disease
Current Rheumatology Reviews Smart Inulin-Based Polycationic Nanodevices for siRNA Delivery
Current Drug Delivery Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target
Current Topics in Medicinal Chemistry High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA Cyclooxygenase-2 Biology
Current Pharmaceutical Design New Analogues of Mycophenolic Acid
Mini-Reviews in Medicinal Chemistry Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Abnormal Signal Transduction via Over-expression of Pim-1 Regulated Senescence, Cell Cycle, Apoptosis and Metastatic Invasion: Novel Anticancer Targets and Their Potent Inhibitors from Marine Sources
Current Signal Transduction Therapy VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line
Current Gene Therapy Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes
Mini-Reviews in Medicinal Chemistry Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Effect of Pinocembrin Isolated from Boesenbergia pandurata on Xenobiotic-Metabolizing Enzymes in Rat Liver
Drug Metabolism Letters Development of New Potential Anticancer Metal Complexes Derived from 2-Hydrazinobenzothiazole
Mini-Reviews in Medicinal Chemistry Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism